About Inbiomotion
Inbiomotion is a company based in Barcelona (Spain) founded in 2010. Inbiomotion has raised $4.91 million across 5 funding rounds from investors including European Commission, European Union and Alta Life Sciences. Inbiomotion operates in a competitive market with competitors including OncoStem, Curasight, PreludeDx, Miltel and POC Medical Systems, among others.
- Headquarter Barcelona, Spain
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.91 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
European Commission
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Inbiomotion
Unlock access to complete
Unlock access to complete
Leadership Team
4 people
Advisor Team
3 people
Advisory Team
1 people
Founder Team
1 people
Unlock access to complete
Funding Insights of Inbiomotion
Inbiomotion has successfully raised a total of $4.91M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inbiomotion
Inbiomotion has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include European Commission, European Union and Alta Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Locked | Locked | Locked | |
|
Venture capital investments are focused on healthcare and multiple sectors.
|
Locked | Locked | Locked |
Investor details for Inbiomotion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inbiomotion
Investment portfolio details for Inbiomotion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inbiomotion
Detailed financials for Inbiomotion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inbiomotion Comparisons
Peer comparison for Inbiomotion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inbiomotion
Inbiomotion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OncoStem, Curasight, PreludeDx, Miltel and POC Medical Systems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Prognostic tests for cancer detection and recurrence risk are developed.
|
|
| Locked | Locked | Locked |
uPAR-based PET ligands for breast cancer imaging are developed.
|
|
| Locked | Locked | Locked |
Risk assessment tests for early-stage breast cancer are provided.
|
|
| Locked | Locked | Locked |
Telomere tests for aging detection and cellular senescence are provided.
|
|
| Locked | Locked | Locked |
Develops rapid tools for breast cancer detection and disease screening worldwide.
|
Detailed competitors of Inbiomotion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inbiomotion
Complete news archive for Inbiomotion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inbiomotion
Inbiomotion was founded in 2010 and raised its 1st funding round 2 years after it was founded.
Inbiomotion is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Inbiomotion is a funded company, having raised a total of $4.91M across 5 funding rounds to date.
Inbiomotion was founded in 2010 in Barcelona, Spain, within the biotechnology sector. Biomarkers are developed by the company to predict bone metastasis risks in cancer patients. A specific biomarker was identified in primary breast tumors to forecast bone relapse, regardless of other clinical parameters. This approach is currently being evaluated across multiple solid tumor types.
Inbiomotion has 6 investors. Key investors include European Commission, European Union, Alta Life Sciences, Ysios Capital, and Caixa Capital Risc.